A Phase 3 interventional study of Tavapadon and Placebo in Parkinson Disease, sponsored by AbbVie. Completed at 77 sites in 12 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.
Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 5th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2019.
This study's enrollment of 529 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 57 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 3 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
44 studies in Parkinson Disease by AbbVie: 6 open now, 9 under way, none of them phase 3. Of 33 finished, 18 (55%) have results posted.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 2nd largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2019, is one of 16 in phase 3, and was the 23rd registered.
AbbVie’s Parkinson Disease studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing tavapadon in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 44 in Parkinson Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
Key Inclusion Criteria:
Key Exclusion Criteria:
Participants with any of the following abnormalities in clinical laboratory tests at the Screening Visit, as assessed by the central laboratory and confirmed by a single repeat measurement, if deemed necessary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tavapadon tablet titrated up to 5 milligram (mg) once daily (QD) orally for 27 weeks.
Drug: Tavapadon
Participants will receive tavapadon tablet titrated up to 15 milligram (mg) QD orally for 27 weeks.
Drug: Tavapadon
Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
Drug: Placebo
Participants will be randomized to receive tavapadon 5mg tablet once daily orally for 27 weeks.
Also known as: PF-06649751, CVL-751
Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Participants will be randomized to receive tavapadon 15mg tablet once daily orally for 27 weeks.
Also known as: PF-06649751, CVL-751
Change From Baseline in the MDS-UPDRS Parts II and III Combined Score
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.
Time frame: Week 26
Change From Baseline in the MDS-UPDRS Part II Score
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.
Time frame: Week 26
Percentage of Responders With a Score of "Much Improved" or "Very Much Improved" on PGIC
The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.
Time frame: Week 26
Change From Baseline in the MDS-UPDRS Parts II and III Combined Score
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.
Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27
Change From Baseline in the MDS-UPDRS Parts I, II and III Combined Score
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 1, 2, and 3 combined is the sum of Part 1, Part 2, and Part 3 scores at each assessment time for each participant. The combined score assesses 44 items with score range: 0-236.
Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27
Change From Baseline in the MDS-UPDRS Parts I, II and III Individual Score
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.
Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27
Change From Baseline in the CGI-S Score
The Global Impression - Severity of Illness (CGI-S) Score is a clinician's impression of a participant's severity of illness on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (normal) to 7 (among the most extremely ill participants). Higher values represent a worse outcome.
Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27
Change From Baseline in the CGI-I Score
The Clinical Global Impression - Improvement (CGI-I) Score is a clinician's impression of how much the participant's illness has improved or worsened relative to the baseline on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.
Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27
Change From Baseline in the PGIC Score
The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.
Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27
Change From Baseline in the Epworth Sleepiness Scale (ESS)
The ESS is an 8-question, participant questionnaire that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated on a 4-point (0-3) scale with scores ranging from 0 (would never nod off) to 3 (high chance of nodding off). Higher values represent a worse outcome.
Time frame: Week 26
Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)
QUIP-RS is a questionnaire for impulse-compulsive disorders in Parkinson's disease rating scale to assess impulse control disorders (ICD). The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \[0 means "never" and 4 means "very often"\] for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112. A higher score indicating greater severity of symptoms.
Time frame: Week 26
Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation (SI) categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.
Time frame: Week 27
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 190 days following last dose of study drug.
In this Phase 3, Double-Blind study, a total of 529 subjects with Parkinson's Disease (PD) were randomized in a 1:1:1 ratio to 3 treatment groups: Tavapadon 5 mg, Tavapadon 15 mg, or Placebo once daily (QD) for 27 Weeks.
| Milestone | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Started | 175 | 177 | 177 |
| Completed | 148 | 134 | 118 |
| Not completed | 27 | 43 | 59 |
| Withdrew: Adverse event | 6 | 29 | 35 |
| Withdrew: Death | 2 | 1 | 0 |
| Withdrew: Lack of efficacy | 5 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 1 |
| Withdrew: Treatment with prohibited concomitant medications | 0 | 0 | 1 |
| Withdrew: Non-compliance with study schedule | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 5 | 3 | 1 |
| Withdrew: Withdrawal by subject | 7 | 8 | 15 |
| Withdrew: Other | 0 | 1 | 2 |
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | 1.8 ± 0.82 | -9.7 ± 0.86 | -10.2 ± 0.88 |
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Change From Baseline in the MDS-UPDRS Part II Score | 0.9 ± 0.30 | -1.6 ± 0.31 | -1.7 ± 0.32 |
The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.
| Participants | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Percentage of Responders With a Score of "Much Improved" or "Very Much Improved" on PGIC | 18 | 60 | 52 |
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Week 5 | -1.2 ± 0.57 | -4.4 ± 0.59 | -4.7 ± 0.59 |
| Week 8 | -2.2 ± 0.62 | -6.9 ± 0.65 | -6.7 ± 0.65 |
| Week 11 | -0.9 ± 0.72 | -8.1 ± 0.75 | -9.1 ± 0.75 |
| Week 14 | -1.2 ± 0.74 | -8.8 ± 0.78 | -9.4 ± 0.78 |
| Week 18 | 0.4 ± 0.78 | -9.1 ± 0.82 | -9.7 ± 0.83 |
| Week 22 | 0.4 ± 0.81 | -9.6 ± 0.84 | -10.9 ± 0.86 |
| Week 26 | 1.8 ± 0.82 | -9.7 ± 0.86 | -10.2 ± 0.88 |
| Week 27 | 2.2 ± 0.92 | -8.6 ± 0.96 | -10.0 ± 0.99 |
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 1, 2, and 3 combined is the sum of Part 1, Part 2, and Part 3 scores at each assessment time for each participant. The combined score assesses 44 items with score range: 0-236.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Week 5 | -1.2 ± 0.67 | -3.9 ± 0.69 | -4.0 ± 0.69 |
| Week 8 | -2.6 ± 0.72 | -6.4 ± 0.76 | -6.2 ± 0.75 |
| Week 11 | -1.2 ± 0.81 | -7.7 ± 0.86 | -8.6 ± 0.86 |
| Week 14 | -1.5 ± 0.85 | -8.8 ± 0.89 | -8.7 ± 0.90 |
| Week 18 | 0.3 ± 0.91 | -9.3 ± 0.95 | -9.1 ± 0.96 |
| Week 22 | 0.2 ± 0.94 | -9.5 ± 0.98 | -10.3 ± 1.00 |
| Week 26 | 2.3 ± 0.95 | -9.4 ± 1.00 | -9.7 ± 1.02 |
| Week 27 | 2.4 ± 1.06 | -8.5 ± 1.11 | -9.4 ± 1.14 |
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Part I: Week 5 | 0.0 ± 0.23 | 0.6 ± 0.24 | 0.7 ± 0.24 |
| Part I: Week 8 | -0.4 ± 0.23 | 0.5 ± 0.24 | 0.4 ± 0.24 |
| Part I: Week 11 | -0.3 ± 0.23 | 0.4 ± 0.24 | 0.4 ± 0.25 |
| Part I: Week 14 | -0.2 ± 0.25 | 0.0 ± 0.27 | 0.6 ± 0.27 |
| Part I: Week 18 | -0.1 ± 0.25 | -0.2 ± 0.26 | 0.5 ± 0.27 |
| Part I: Week 22 | -0.2 ± 0.26 | 0.2 ± 0.27 | 0.4 ± 0.28 |
| Part I: Week 26 | 0.5 ± 0.27 | 0.2 ± 0.28 | 0.4 ± 0.29 |
| Part I: Week 27 | 0.2 ± 0.27 | 0.2 ± 0.28 | 0.3 ± 0.29 |
| Part II: Week 5 | -0.2 ± 0.22 | -0.8 ± 0.23 | -1.0 ± 0.22 |
| Part II: Week 8 | -0.5 ± 0.23 | -1.0 ± 0.25 | -1.6 ± 0.24 |
| Part II: Week 11 | 0.0 ± 0.26 | -1.7 ± 0.27 | -2.0 ± 0.27 |
| Part II: Week 14 | -0.1 ± 0.27 | -1.6 ± 0.28 | -2.0 ± 0.28 |
| Part II: Week 18 | 0.4 ± 0.29 | -1.9 ± 0.31 | -1.8 ± 0.31 |
| Part II: Week 22 | 0.3 ± 0.28 | -1.7 ± 0.29 | -2.1 ± 0.29 |
| Part II: Week 26 | 0.9 ± 0.30 | -1.6 ± 0.31 | -1.7 ± 0.32 |
| Part II: Week 27 | 0.9 ± 0.31 | -1.7 ± 0.32 | -1.8 ± 0.33 |
| Part III: Week 5 | -1.0 ± 0.44 | -3.7 ± 0.46 | -3.7 ± 0.45 |
| Part III: Week 8 | -1.7 ± 0.50 | -6.0 ± 0.52 | -5.1 ± 0.52 |
| Part III: Week 11 | -1.0 ± 0.55 | -6.5 ± 0.58 | -7.1 ± 0.59 |
| Part III: Week 14 | -1.1 ± 0.58 | -7.2 ± 0.61 | -7.4 ± 0.61 |
| Part III: Week 18 | 0.0 ± 0.60 | -7.3 ± 0.63 | -7.9 ± 0.64 |
| Part III: Week 22 | 0.0 ± 0.64 | -8.0 ± 0.67 | -8.8 ± 0.68 |
| Part III: Week 26 | 0.9 ± 0.63 | -8.1 ± 0.66 | -8.5 ± 0.68 |
| Part III: Week 27 | 1.1 ± 0.71 | -7.1 ± 0.75 | -8.3 ± 0.77 |
The Global Impression - Severity of Illness (CGI-S) Score is a clinician's impression of a participant's severity of illness on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (normal) to 7 (among the most extremely ill participants). Higher values represent a worse outcome.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Week 5 | 0.0 ± 0.04 | -0.1 ± 0.05 | 0.0 ± 0.05 |
| Week 8 | 0.0 ± 0.05 | -0.1 ± 0.05 | -0.1 ± 0.05 |
| Week 11 | 0.0 ± 0.05 | -0.2 ± 0.05 | -0.3 ± 0.05 |
| Week 14 | 0.1 ± 0.05 | -0.2 ± 0.05 | -0.3 ± 0.05 |
| Week 18 | 0.1 ± 0.05 | -0.3 ± 0.06 | -0.3 ± 0.06 |
| Week 22 | 0.1 ± 0.05 | -0.2 ± 0.06 | -0.3 ± 0.06 |
| Week 26 | 0.2 ± 0.05 | -0.3 ± 0.05 | -0.2 ± 0.06 |
| Week 27 | 0.1 ± 0.05 | -0.2 ± 0.06 | -0.2 ± 0.06 |
The Clinical Global Impression - Improvement (CGI-I) Score is a clinician's impression of how much the participant's illness has improved or worsened relative to the baseline on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Week 5 | 3.8 ± 0.06 | 3.4 ± 0.06 | 3.4 ± 0.06 |
| Week 8 | 3.8 ± 0.06 | 3.2 ± 0.07 | 3.3 ± 0.07 |
| Week 11 | 3.8 ± 0.07 | 3.0 ± 0.08 | 3.1 ± 0.08 |
| Week 14 | 3.8 ± 0.07 | 3.0 ± 0.08 | 3.0 ± 0.08 |
| Week 18 | 3.9 ± 0.08 | 2.8 ± 0.08 | 2.9 ± 0.08 |
| Week 22 | 3.9 ± 0.08 | 2.9 ± 0.09 | 3.0 ± 0.09 |
| Week 26 | 3.9 ± 0.09 | 2.8 ± 0.09 | 3.0 ± 0.09 |
| Week 27 | 4.0 ± 0.09 | 2.8 ± 0.09 | 2.9 ± 0.09 |
The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Week 5 | 3.7 ± 0.07 | 3.5 ± 0.07 | 3.4 ± 0.07 |
| Week 8 | 3.8 ± 0.08 | 3.2 ± 0.08 | 3.2 ± 0.08 |
| Week 11 | 3.8 ± 0.08 | 3.0 ± 0.08 | 3.1 ± 0.08 |
| Week 14 | 3.8 ± 0.08 | 2.8 ± 0.09 | 3.0 ± 0.09 |
| Week 18 | 3.9 ± 0.09 | 2.8 ± 0.10 | 2.9 ± 0.10 |
| Week 22 | 3.8 ± 0.09 | 2.9 ± 0.10 | 2.9 ± 0.10 |
| Week 26 | 4.0 ± 0.10 | 2.8 ± 0.10 | 2.8 ± 0.11 |
| Week 27 | 4.0 ± 0.10 | 2.8 ± 0.11 | 2.9 ± 0.11 |
The ESS is an 8-question, participant questionnaire that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated on a 4-point (0-3) scale with scores ranging from 0 (would never nod off) to 3 (high chance of nodding off). Higher values represent a worse outcome.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Change From Baseline in the Epworth Sleepiness Scale (ESS) | -0.2 ± 0.23 | -0.3 ± 0.24 | -0.5 ± 0.24 |
QUIP-RS is a questionnaire for impulse-compulsive disorders in Parkinson's disease rating scale to assess impulse control disorders (ICD). The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \[0 means "never" and 4 means "very often"\] for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112. A higher score indicating greater severity of symptoms.
| score on a scale | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) | -2.1 ± 0.46 | -2.2 ± 0.47 | -2.4 ± 0.48 |
The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation (SI) categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.
| Participants | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Participants With Any Suicidal Ideations | 3 | 3 | 3 |
| Participants With Any Suicidal Behaviors | 0 | 0 | 0 |
| Participants With Any Suicidal Behaviors or Ideations | 3 | 3 | 3 |
| Participants With Non-Suicidal Self-Injurious Behavior | 0 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| Participants | Placebo | Tavapadon 5 mg | Tavapadon 15 mg |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 100 | 142 | 139 |
Collected over All-cause mortality was reported from enrollment until 4 weeks after the last dose of study drug. Treatment-emergent adverse events and serious adverse events were collected from the first dose of study drug until 4 weeks after the dose of study drug for all Arms. Mean duration on study drug was 27 weeks. Median time on study was 190, 190, 189 days for Placebo, Tavapadon 5 mg, and Tavapadon 15 mg, respectively.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/175 (1.1%) | 11/175 (6.3%) | 72/175 (41.1%) |
| Tavapadon 5mg QD | 1/177 (0.6%) | 4/177 (2.3%) | 125/177 (70.6%) |
| Tavapadon 15mg QD | 0/177 (0%) | 10/177 (5.6%) | 125/177 (70.6%) |
| Event | Placebo | Tavapadon 5mg QD | Tavapadon 15mg QD |
|---|---|---|---|
| COVID-19Infections and infestations | 3/175 | 0/177 | 0/177 |
| COVID-19 PNEUMONIAInfections and infestations | 2/175 | 0/177 | 0/177 |
| PNEUMONIAInfections and infestations | 1/175 | 0/177 | 2/177 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/175 | 0/177 | 0/177 |
| INGUINAL HERNIAGastrointestinal disorders | 1/175 | 0/177 | 0/177 |
| FALLInjury, poisoning and procedural complications | 1/175 | 0/177 | 0/177 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 1/175 | 0/177 | 0/177 |
| HEAD INJURYInjury, poisoning and procedural complications | 1/175 | 0/177 | 0/177 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/175 | 0/177 | 0/177 |
| PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/175 | 0/177 | 0/177 |
| Event | Placebo | Tavapadon 5mg QD | Tavapadon 15mg QD |
|---|---|---|---|
| NAUSEAGastrointestinal disorders | 3/175 | 42/177 | 48/177 |
| HEADACHENervous system disorders | 9/175 | 22/177 | 37/177 |
| DIZZINESSNervous system disorders | 8/175 | 24/177 | 21/177 |
| FATIGUEGeneral disorders | 6/175 | 10/177 | 16/177 |
| DYSGEUSIANervous system disorders | 0/175 | 14/177 | 14/177 |
| VOMITINGGastrointestinal disorders | 1/175 | 12/177 | 9/177 |
| DRY MOUTHGastrointestinal disorders | 0/175 | 11/177 | 9/177 |
| ORTHOSTATIC HYPOTENSIONVascular disorders | 0/175 | 11/177 | 4/177 |
| DYSPEPSIAGastrointestinal disorders | 2/175 | 5/177 | 10/177 |
| ABNORMAL DREAMSPsychiatric disorders | 1/175 | 10/177 | 6/177 |
Includes all enrolled subjects that received at least one dose of study drug.
| Age, Continuous(years) | Placebo | Tavapadon 5 mg | Tavapadon 15 mg | Total |
|---|---|---|---|---|
| Mean | 63.5 ± 9.62 | 63.7 ± 9.80 | 63.8 ± 9.40 | 63.7 ± 9.59 |
| Sex: Female, Male(Participants) | Placebo | Tavapadon 5 mg | Tavapadon 15 mg | Total |
|---|---|---|---|---|
| Female | 63 | 66 | 58 | 187 |
| Male | 112 | 111 | 119 | 342 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tavapadon 5 mg | Tavapadon 15 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 13 | 10 | 32 |
| Not Hispanic or Latino | 154 | 153 | 158 | 465 |
| Unknown or Not Reported | 12 | 11 | 9 | 32 |
| Race (NIH/OMB)(Participants) | Placebo | Tavapadon 5 mg | Tavapadon 15 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 3 | 0 | 2 | 5 |
| White | 168 | 174 | 172 | 514 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 2 | 1 | 2 | 5 |
| MDS-UPDRS Score at Baseline (Parts II and III Combined)(units on a scale) | Placebo | Tavapadon 5 mg | Tavapadon 15 mg | Total |
|---|---|---|---|---|
| Mean | 32.0 ± 9.96 | 31.3 ± 10.87 | 32.1 ± 11.55 | 31.8 ± 10.80 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Jun 2024, 54 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 54 months is above that.
Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tavapadon